Page last updated: 2024-09-05

succinobucol and probucol

succinobucol has been researched along with probucol in 52 studies

Compound Research Comparison

Studies
(succinobucol)
Trials
(succinobucol)
Recent Studies (post-2010)
(succinobucol)
Studies
(probucol)
Trials
(probucol)
Recent Studies (post-2010) (probucol)
535161,488174317

Protein Interaction Comparison

ProteinTaxonomysuccinobucol (IC50)probucol (IC50)
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)1.6

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's33 (63.46)29.6817
2010's19 (36.54)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hill, RR; Holt, LA; Hoong, LK; Kunsch, C; Meng, CQ; Olliff, LK; Parthasarathy, S; Rachita, CL; Saxena, U; Sikorski, JA; Simpson, JE; Somers, PK; Sundell, CL; Wasserman, MA; Zheng, XS1
Hill, RR; Hoong, LK; Hotema, MR; Howard, RB; Kunsch, C; Landers, LK; Luchoomun, J; MacDOnald, ML; Marino, EM; Meng, CQ; Saxena, U; Sikorski, JA; Simpson, JE; Somers, PK; Stefanopoulos, D; Suen, KL; Sundell, CL; Wasserman, MA; Weingarten, MD; Worsencroft, KJ; Ye, Z; Zheng, XS1
Senior, K1
Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L1
Alexander, RW; Butteiger, D; Chapman, A; Daugherty, A; Edwards, D; Hill, RR; Hoong, LK; Jones, M; Landers, LK; Medford, RM; Meng, CQ; Saxena, U; Somers, PK; Suen, KL; Sundell, CL; Wasserman, MA1
Edwards, D; Kunsch, C; Medford, RM; Meng, CQ; Sundell, CL; Wasserman, MA1
Tardif, JC3
Stix, G1
Doggrell, SA1
Arrendale, RF; Grey, JY; Kunsch, C; Luchoomun, J; Medford, RM; Olliff, LK; Saint, LB; Saxena, U; Wasserman, MA1
Grégoire, J; L'Allier, PL; Lavoie, MA; Tardif, JC2
Franks, AM; Gardner, SF1
Cynshi, O; Stocker, R1
Ransom, J1
Malinin, A; Scott, R; Serebruany, V1
Veryard, C1
Anderson, TJ; Bertrand, OF; Brennan, ML; Grégoire, J; Guertin, MC; Hazen, SL; Ibrahim, R; L'Allier, PL; LeMay, M; Lespérance, J; Reeves, F; Schampaert, E; Scott, R; Tardif, JC; Title, LM1
Preiss, DJ; Sattar, N1
Benson, AP; Christensen, VL; Davis, AJ; Fairchild, BD; Hoffman, JB1
Tanimoto, T1
Eisert, C; Malinin, A; Ong, S; Serebruany, VL1
Douglas, JS1
Horowitz, J; Kaski, JC; McMurray, JJ; Recio-Mayoral, A; Remme, WJ; van Veldhuisen, DJ1
Dart, AM; Duffy, SJ1
Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC1
Kunsch, C; Malinin, A; Qiu, FH; Scott, R; Serebruany, V; Xu, XC1
Li, G; Liu, T1
Franks, AM; Muldrew, KM1
Stocker, R1
Beck, K; Cassano, C; Changsiri, D; Gamble, JR; Midwinter, RG; Stocker, R; Wang, Y; Wu, BJ1
Lovering, RM; Michaelson, L; Ward, CW1
Carter, JD; Cole, BK; Crim, WS; Kunsch, C; Mirmira, RG; Nadler, JL; Nunemaker, CS; Trace, AP; Wu, R1
Inazu, A1
Buřičová, L; Drašar, P; Galandáková, A; Horníček, J; Ikonen, S; Jurček, O; Kolehmainen, ET; Ulrichová, J; Wimmer, Z; Wimmerová, M1
Belikova, NA; Cai, H; Dennis, JM; Dong, LF; Kagan, VE; Kapralov, AA; Khachigian, L; Maghzal, GJ; Midwinter, RG; Neuzil, J; Stocker, R; Tyurina, YY; Wu, BJ1
Drašar, P; Jurček, O; Kolehmainen, E; Lahtinen, M; Wimmer, Z1
Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J1
Gómez, G; Lagakos, SW1
Biswal, S1
Braga, AL; Colle, D; Farina, M; Godoi, M; Hartwig, JM; Santos, DB1
Kourounakis, AP; Ladopoulou, E; Matralis, AN1
Belik, J; Kasirer, MY; Pan, J; Shifrin, Y; Welsh, C1
Cao, H; Chen, L; Gu, W; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z; Zhao, S1
Braga, AL; Colle, D; de Bem, AF; Engel, DF; Farina, M; Godoi, M; Hartwig, JM; Santos, DB1
Bao, X; Cao, H; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z1
Cao, H; Dan, Z; He, X; Li, Y; Shen, Q; Xu, M; Xu, Y; Yin, Q; Yu, H; Zeng, L; Zhang, P; Zhang, Z; Zhong, D; Zou, L1
Braga, AL; Colle, D; Dias, PF; Farina, M; Ghizoni, H; Godoi, M; Gonçalves, CL; Hort, MA; Naime, AA; Ribeiro, RP; Santos, DB1
Gnanadesikan, S; Houston, SA; Kennedy, S; Ugusman, A1
Chen, Y; Liu, Z; Shi, S; Wang, X; Zhang, Y; Zheng, Z; Zhu, H1

Reviews

16 review(s) available for succinobucol and probucol

ArticleYear
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
    The American journal of cardiology, 2003, Feb-06, Volume: 91, Issue:3A

    Topics: Antioxidants; Arteriosclerosis; Cardiovascular System; Coronary Artery Disease; Humans; Probucol; Signal Transduction

2003
Clinical results with AGI-1067: a novel antioxidant vascular protectant.
    The American journal of cardiology, 2003, Feb-06, Volume: 91, Issue:3A

    Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Humans; Oxidative Stress; Probucol

2003
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
    Expert opinion on investigational drugs, 2003, Volume: 12, Issue:11

    Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Disease Models, Animal; Endothelium, Vascular; Humans; Probucol

2003
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
    Current opinion in lipidology, 2003, Volume: 14, Issue:6

    Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; ortho-Aminobenzoates; Oxidative Stress; Probucol; Sirolimus; Vitamins

2003
Vascular protectants for the treatment of atherosclerosis.
    Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:3

    Topics: Antioxidants; Coronary Artery Disease; Humans; Probucol; Protective Agents; Randomized Controlled Trials as Topic; Research Design

2003
Antioxidants and atherosclerosis: emerging drug therapies.
    Current atherosclerosis reports, 2005, Volume: 7, Issue:1

    Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Humans; Oxidative Stress; Probucol

2005
AGI-1067: a novel vascular protectant for prevention of restenosis.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:1

    Topics: Animals; Antioxidants; Clinical Trials as Topic; Coronary Restenosis; Drugs, Investigational; Humans; Molecular Structure; Probucol

2006
Antioxidants: the good, the bad and the ugly.
    The Canadian journal of cardiology, 2006, Volume: 22 Suppl B

    Topics: Angioplasty, Balloon, Coronary; Antioxidants; Atherosclerosis; Coronary Restenosis; Humans; Oxidative Stress; Probucol; Vitamins

2006
Inhibition of lipoprotein lipid oxidation.
    Handbook of experimental pharmacology, 2005, Issue:170

    Topics: Animals; Antioxidants; Atherosclerosis; Benzofurans; Cardiovascular Diseases; Humans; Lipoproteins, LDL; Malondialdehyde; Oxidation-Reduction; Probucol; Thiobarbituric Acid Reactive Substances

2005
Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
    International journal of clinical practice, 2007, Volume: 61, Issue:4

    Topics: Antioxidants; Atherosclerosis; Endothelium, Vascular; Evidence-Based Medicine; Gene Expression Regulation; Humans; Probucol; Vascular Cell Adhesion Molecule-1

2007
[Research and developmental strategy of anti-dyslipidemic agents].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2007, Volume: 129, Issue:4

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Disease Models, Animal; Drug Design; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Oligoribonucleotides, Antisense; Probucol; Receptors, G-Protein-Coupled; Receptors, Nicotinic

2007
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:4

    Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosis; Cytokines; Disease Progression; Humans; Hypolipidemic Agents; Oxidative Stress; Platelet Aggregation Inhibitors; Probucol; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2007
Pharmacologic approaches to restenosis prevention.
    The American journal of cardiology, 2007, Sep-03, Volume: 100, Issue:5A

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome

2007
Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:4

    Topics: Animals; Cardiovascular System; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Platelet Aggregation Inhibitors; Probucol

2009
Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
    Current opinion in lipidology, 2009, Volume: 20, Issue:3

    Topics: Animals; Atherosclerosis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Probucol

2009
[Novel therapy for atherosclerosis and inflammatory vascular disease].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69, Issue:1

    Topics: Acetates; Amides; Apolipoprotein A-I; Atherosclerosis; Benzaldehydes; Blood Proteins; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Drug Design; Esters; Humans; Indoles; Keto Acids; Molecular Targeted Therapy; Oxazolidinones; Oximes; Probucol; Quinazolines; Quinazolinones; Sulfhydryl Compounds

2011

Trials

5 trial(s) available for succinobucol and probucol

ArticleYear
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
    Circulation, 2003, Feb-04, Volume: 107, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary Disease; Coronary Restenosis; Coronary Vessels; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Probucol; Stents; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency

2003
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
    Atherosclerosis, 2008, Volume: 197, Issue:1

    Topics: Aged; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peroxidase; Probucol; Treatment Outcome; Ultrasonography, Interventional

2008
Novel cardiac therapies and innocent by standers.
    Lancet (London, England), 2008, May-24, Volume: 371, Issue:9626

    Topics: Antioxidants; Coronary Disease; Double-Blind Method; Humans; Probucol

2008
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2008, May-24, Volume: 371, Issue:9626

    Topics: Acute Coronary Syndrome; Adult; Aged; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Probucol

2008
Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
    Journal of thrombosis and thrombolysis, 2009, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Biomarkers; Cells, Cultured; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Lipoproteins; Male; Middle Aged; Probucol; Risk Factors; Thromboxanes; Vascular Diseases; Young Adult

2009

Other Studies

31 other study(ies) available for succinobucol and probucol

ArticleYear
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
    Bioorganic & medicinal chemistry letters, 2002, Sep-16, Volume: 12, Issue:18

    Topics: Animals; Antioxidants; Arteriosclerosis; Humans; Phenols; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2002
Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
    Journal of medicinal chemistry, 2004, Dec-02, Volume: 47, Issue:25

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antioxidants; Cells, Cultured; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Cricetinae; Depression, Chemical; Endothelial Cells; Endothelium, Vascular; Humans; Inflammation; Interleukin-1; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Phenols; Probucol; Structure-Activity Relationship; Sulfides; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2004
Drug reverses coronary atherosclerosis.
    Drug discovery today, 2002, Jan-01, Volume: 7, Issue:1

    Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Vessels; Humans; Probucol

2002
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease Models, Animal; Endothelium, Vascular; Humans; Lipid Metabolism; Macaca fascicularis; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Probucol

2003
Signal jammer. An academic experiment leads to a new class of drug for attacking heart disease.
    Scientific American, 2003, Volume: 289, Issue:1

    Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; Heart Diseases; Humans; Probucol

2003
Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 308, Issue:3

    Topics: Active Transport, Cell Nucleus; Anti-Inflammatory Agents; Antioxidants; Aorta; Cells, Cultured; Cytokines; Drug Interactions; Endothelium, Vascular; Gene Expression; Humans; Leukocytes, Mononuclear; Monocytes; NF-kappa B; Oxidation-Reduction; Probucol; Transcriptional Activation; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2004
Are small biotechs still underselling themselves?
    Nature biotechnology, 2006, Volume: 24, Issue:5

    Topics: Biotechnology; Capital Financing; Drug Industry; Heart; Humans; Inflammation; Investments; Marketing; Myocardium; Probucol; Research Support as Topic; Technology, Pharmaceutical

2006
The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
    Journal of cardiovascular pharmacology and therapeutics, 2006, Volume: 11, Issue:3

    Topics: Adult; Antigens, CD; Antioxidants; Baltimore; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Female; Flow Cytometry; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation; Platelet Membrane Glycoproteins; Probucol; Receptors, Cell Surface; Risk Factors; Vascular Diseases

2006
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:1

    Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Erythropoietin; Extremities; Fibroblast Growth Factor 2; Humans; Ischemia; Lipid Metabolism Disorders; Myocardial Infarction; Niacin; Probucol

2007
Follicular development and expression of the messenger ribonucleic acid for the inhibin/activin subunits in two genetic lines of turkey hens that differ in total egg production.
    Poultry science, 2007, Volume: 86, Issue:5

    Topics: Activins; Animals; Female; Follistatin; Gene Expression Regulation; Inhibins; Ovarian Follicle; Oviposition; Probucol; Protein Subunits; RNA, Messenger; Turkeys

2007
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
    Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:6

    Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as Topic; Clopidogrel; Electrocardiography; Europe; Fumarates; Heart Diseases; Heart Failure; Hirudins; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptide Fragments; Probucol; Recombinant Proteins; Ticlopidine; Tolvaptan

2007
Probucol and succinobucol in atrial fibrillation: pros and cons.
    International journal of cardiology, 2010, Oct-08, Volume: 144, Issue:2

    Topics: Anticholesteremic Agents; Atrial Fibrillation; Humans; Probucol

2010
Heme oxygenase-1 increases endothelial progenitor cells.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:10

    Topics: Animals; Antigens, Ly; Carbon Monoxide; Cells, Cultured; Endothelial Cells; Enzyme Induction; Hematopoietic Stem Cells; Heme Oxygenase-1; Hyperplasia; Membrane Proteins; Mice; Probucol; Rabbits; Tunica Intima; Vascular Endothelial Growth Factor Receptor-2

2009
Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signaling.
    American journal of physiology. Cell physiology, 2009, Volume: 297, Issue:3

    Topics: Animals; Calcium; Calcium Signaling; Dystrophin; Mice; Mice, Inbred mdx; Muscle Contraction; Muscle Fibers, Skeletal; Osmotic Pressure; Probucol; Protein Transport

2009
AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.
    Molecular and cellular endocrinology, 2010, Jul-29, Volume: 323, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Antioxidants; Calcium; Cell Death; Cytokines; Diazoxide; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Keto Acids; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Potassium Channels; Probucol; Tolbutamide

2010
Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
    Molecules (Basel, Switzerland), 2011, Nov-10, Volume: 16, Issue:11

    Topics: 3T3 Cells; Animals; Anti-Inflammatory Agents; Antioxidants; Biological Availability; Biphenyl Compounds; Clinical Trials as Topic; Fibroblasts; Free Radicals; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Picrates; Probucol; Static Electricity; Steroids

2011
Succinobucol induces apoptosis in vascular smooth muscle cells.
    Free radical biology & medicine, 2012, Mar-01, Volume: 52, Issue:5

    Topics: Animals; Aorta; Apoptosis; Caspase 3; Cell Proliferation; Cell Survival; Cells, Cultured; Cytochromes c; DNA Fragmentation; Electron Transport Complex II; Enzyme Induction; Heme Oxygenase-1; Hydrogen Peroxide; Male; Metalloporphyrins; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Probucol; Protoporphyrins; Rabbits; Rats

2012
Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism.
    Journal of pharmaceutical sciences, 2012, Volume: 101, Issue:5

    Topics: Calorimetry, Differential Scanning; Crystallization; Crystallography, X-Ray; Magnetic Resonance Spectroscopy; Models, Molecular; Powder Diffraction; Probucol; Spectrophotometry, Infrared; Thermogravimetry

2012
Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:4

    Topics: Animals; Cardiovascular Agents; Cattle; Cell Survival; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Endothelial Cells; Fibrin; Inflammation; Male; Metals; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Percutaneous Coronary Intervention; Probucol; Prosthesis Design; Sirolimus; Swine

2013
Statistical considerations when using a composite endpoint for comparing treatment groups.
    Statistics in medicine, 2013, Feb-28, Volume: 32, Issue:5

    Topics: Acute Coronary Syndrome; AIDS Vaccines; Anti-HIV Agents; Anticholesteremic Agents; Biostatistics; Endpoint Determination; HIV Infections; Humans; Probucol; Randomized Controlled Trials as Topic

2013
Novel cardiovascular drugs in clinical trials.
    Indian journal of medical sciences, 2010, Volume: 64, Issue:6

    Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes

2010
Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro.
    Mitochondrion, 2013, Volume: 13, Issue:2

    Topics: Animals; Antioxidants; Brain; Electron Transport Complex II; Male; Mitochondria; Nitro Compounds; Oxidative Stress; Probucol; Propionates; Rats; Rats, Wistar

2013
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
    Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

    Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats

2013
Metoclopramide does not increase gastric muscle contractility in newborn rats.
    American journal of physiology. Gastrointestinal and liver physiology, 2014, Mar-01, Volume: 306, Issue:5

    Topics: Animals; Animals, Newborn; Dopamine Antagonists; Electrophysiological Phenomena; Gastrointestinal Transit; Metoclopramide; Muscle Contraction; Muscle, Smooth; Probucol; Random Allocation; Rats; Rats, Sprague-Dawley; Stomach

2014
Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, May-10, Volume: 205

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Breast Neoplasms; Cell Movement; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Female; Hydrophobic and Hydrophilic Interactions; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Particle Size; Poloxamer; Probucol; Rats, Sprague-Dawley; RAW 264.7 Cells; Signal Transduction; Technology, Pharmaceutical; Tissue Distribution; Vascular Cell Adhesion Molecule-1

2015
Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity.
    Molecular neurobiology, 2016, Volume: 53, Issue:2

    Topics: Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Cell Survival; Glutamate-Cysteine Ligase; Glutathione; Glutathione Peroxidase; Humans; Hydroquinones; Hypolipidemic Agents; Mitochondria; Nitro Compounds; Oxidative Stress; Probucol; Propionates; Protective Agents; RNA, Messenger; Time Factors; Up-Regulation

2016
pH-Responsive Wormlike Micelles with Sequential Metastasis Targeting Inhibit Lung Metastasis of Breast Cancer.
    Advanced healthcare materials, 2016, Feb-18, Volume: 5, Issue:4

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Female; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Probucol; RAW 264.7 Cells; Vascular Cell Adhesion Molecule-1

2016
A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer.
    Theranostics, 2016, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Cell Movement; Disease Models, Animal; Drug Delivery Systems; Female; Hydrogen-Ion Concentration; Lung Neoplasms; Mice, Inbred BALB C; Nanostructures; Neoplasm Invasiveness; Polyethylene Glycols; Probucol; Treatment Outcome

2016
Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia.
    Behavioural brain research, 2016, May-15, Volume: 305

    Topics: Adrenergic Agents; Animals; Dose-Response Relationship, Drug; Exploratory Behavior; Feeding Behavior; Forelimb; Glutathione Peroxidase; Glutathione Reductase; Histocompatibility Antigens Class I; Hypokinesia; Injections, Intraventricular; Lipid Peroxidation; Male; Mice; Muscle Strength; Oxidopamine; Peptide Fragments; Probucol; Psychomotor Performance; Thiobarbituric Acid Reactive Substances

2016
An investigation of the antiplatelet effects of succinobucol (AGI-1067).
    Platelets, 2017, Volume: 28, Issue:3

    Topics: Adenosine Diphosphate; Animals; Antioxidants; Blood Platelets; Blood Pressure; Collagen; Heart Rate; Iliac Artery; Male; Myography; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet-Rich Plasma; Probucol; Rabbits; Rats; Rats, Sprague-Dawley; Tissue Culture Techniques; Xanthine; Xanthine Oxidase

2017
Novel ASK1 Inhibitor AGI-1067 Attenuates AGE-Induced Fibrotic Response by Suppressing the MKKs/p38 MAPK Pathway in Human Coronary Arterial Smooth Muscle Cells.
    International heart journal, 2018, Nov-28, Volume: 59, Issue:6

    Topics: Blotting, Western; Cardiovascular Agents; Cells, Cultured; Coronary Vessels; Fibrosis; Glycation End Products, Advanced; Humans; Immunoprecipitation; MAP Kinase Kinase 3; MAP Kinase Kinase 6; MAP Kinase Kinase Kinase 5; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Probucol; Signal Transduction

2018